Envoy Medical, Inc.
0.7844-0.02 (-2.56%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · COCH · USD
Key Stats
Market Cap
22.58MP/E (TTM)
-Basic EPS (TTM)
-1.41Dividend Yield
0%Recent Filings
8-K
Nasdaq listing extension granted
Envoy Medical secured a Nasdaq extension on October 23, 2025, granting until February 23, 2026, to meet the $35 million market value of listed securities rule after failing initial compliance. The panel weighed recent equity raises, debt payoff boosting stockholders' equity, and FDA approval advancing the Acclaim cochlear implant trial, alongside rising shares outstanding to over 28 million and trading volume. Compliance hangs on timely updates. Yet risks loom if milestones slip.
8-K
FDA approves Acclaim trial expansion
Envoy Medical secured FDA approval on October 7, 2025, to expand its pivotal trial for the fully implanted Acclaim cochlear implant to the final stage, following promising three-month data from 10 patients with no serious adverse events. This accelerates full enrollment to early 2026, shortens timelines by three to six months, and trims capital needs by $10-$15 million. No major risks emerged in initial data. Enrollment will surge fast.
8-K
Envoy Medical gains key EU patent
Envoy Medical secured European Patent No. 4338791 on September 17, 2025, for its implantable cochlear system that integrates components and characterizes leads to compensate for middle ear sensor variability. This bolsters the company's global IP portfolio, following recent grants in the US, Australia, and Hong Kong, and safeguards innovations in fully implanted hearing devices like the investigational Acclaim Cochlear Implant. Patents protect groundbreaking tech. Yet regulatory hurdles in clinical trials persist as a key risk.
8-K
Envoy locks in major shareholder support
Envoy Medical inked a Voting and Warrant Extension Agreement on September 4, 2025, with major shareholder Glen A. Taylor and his entities, who control 47.8% of Class A Common Stock. The deal secures their votes for Nasdaq compliance proposals through 2028, extends GAT's 3.5 million warrants to December 31, 2028, and grants registration rights starting March 31, 2026. This bolsters governance stability while easing liquidity for the key investor. Binding on transferees.
8-K
Nasdaq delisting hearing requested
Envoy Medical faces Nasdaq delisting after failing to meet the $35 million market value requirement within the 180-day cure period ending August 26, 2025. The company requested a hearing on August 29, staying suspension until the panel decides. Debt extinguishment bolsters its compliance pitch. Yet risks loom if the appeal fails.
AORT
Artivion, Inc.
44.99-0.27
ENOV
Enovis Corporation
31.99-0.87
HSCS
HeartSciences Inc.
2.97-0.19
INND
Innerscope Hearing Technologies
0.00+0.00
INSP
Inspire Medical Systems, Inc.
75.17-2.00
NVNO
enVVeno Medical Corporation
0.72+0.00
OSSFF
EMBLA MEDICAL
4.79+0.00
SENS
Senseonics Holdings, Inc.
7.25+0.05
SNWV
SANUWAVE Health, Inc.
30.44-0.60
VYCO
Vycor Medical, Inc.
0.15+0.00